CURAVAC, INC.

WILMINGTON, DE · CIK 0001677679 · Biotech · Private

Complementary peptide-based therapeutics for autoimmune diseases

curavac.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$4.7M
1 Form D · Jun 2016
123 months since last filing
Contracts
—
No federal contracts on record
Patents
1
1 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$4,675,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2276ENGAGE BIOLOGICS INC.——
2277Perfect Day, Inc.—$222M
2278Dren Bio, Inc.—$93M
2279CURAVAC, INC.—$4.7M
2280bluebird bio—$179M
2281EFFECTORBIO, INC.——
2282Ensysce Biosciences, Inc.—$103M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Leone FlynnDirector · Executive Officer
  • Nicolas HavelangeDirector · Executive Officer
  • Stephane HubertyDirector · Executive Officer

Patents

USPTO · 1 granted of 1

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.